1 BTC
=
- USD
Ensysce Biosciences, Inc. Common Stock
As of June 1, 2026 at 24:05 UTC
Chart
About Ensysce Biosciences, Inc. Common Stock
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Market Statistics
Trading Metrics
How to Buy ENSC
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ENSC
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesEnsysce Biosciences (NASDAQ: ENSC) shares surged 58.66% to $0.63 on Friday after the company announced a strategic review of alternatives aimed at enhancing shareholder value. The Board is exploring partnerships, licensing arrangements, or asset sales to advance its proprietary TAAP and MPAR platforms for safer opioid medicines.
Several companies are transitioning from strategic announcements to operational execution. Kraig Biocraft Laboratories has begun production of recombinant spider silk and received National Geographic cover feature. Rackspace and Palantir announced a strategic partnership to deploy enterprise AI in production environments. Ensysce Biosciences initiated a formal strategic review to explore partnerships and enhance shareholder value.
DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developments include FDA orphan drug designation for Adolore BioTherapeutics' gene therapy, positive Phase IIb results for Dogwood Therapeutics' Halneuron, and Phase III publication of Vertanical's VER-01 for chronic low back pain.
Ensysce Biosciences advanced multiple clinical initiatives in Q2 2025, including launching a Phase 3 trial for PF614, completing enrollment in an overdose prevention study, and receiving a patent notice for its OUD program.
Ensysce Biosciences reported Q2 2025 results, advancing its PF614 opioid program to Phase 3 and achieving milestones in overdose-protection studies. The company reported a narrower GAAP loss of $(0.79) per share, with revenue primarily from federal grants.